Key features of the included studies
Author | Year | Location | Sample size | Participant age | Cancer stage | Treatment stage |
---|---|---|---|---|---|---|
Ene | 2006 | Sweden | 123 | 63.1 | No data provided | Pretreatment to Post-treatment |
Pirl | 2008 | USA | 50 | 62 | Advanced | Pre and On-treatment |
Sharpley | 2007 | Australia | 195 | 69.2 | Localised | Post-treatment |
Bisson | 2002 | Wales | 83 | 64.5 | Mixed | Pretreatment |
Dirkson | 2009 | USA | 51 | 73.4 | Mixed | On-treatment |
Dale | 2009 | USA | 67 | 67.9 | No data provided | Pretreatment (but all participants had received prior primary therapy) |
Gabershagen | 2007 | Germany | 115 | 64.1 | Localised | Pretreatment |
Gabershagen | 2009 | Germany | 84 | 62.8 | Mixed | Pretreatment to post-treatment |
Hervouet | 2005 | Canada | 861 | 67.9 | Mixed | Post-treatment |
Monga | 1999 | USA | 36 | 66 | Localised | Pretreatment to On-treatment to Post-treatment |
Monga | 2005 | USA | 40 | 67.8 | Localised | Pretreatment to On-treatment to Post-treatment |
Pirl | 2002 | USA | 45 | 69.4 | Localised and Metastatic | On-treatment |
Savard | 2005 | Canada | 327 | 66 | localised | Post-treatment |
Stone | 2000 | England | 62 | 69 | Mixed | On-treatment |
Soloway | 2004 | USA | 103 | 62 | No data provided | Pretreatment |
Steineck | 2002 | Finland | 326 | 64.5 | Localised | Post-treatment |
Symon | 2006 | USA | 50 | 59.9 | Localised | Pretreatment to Post-treatment |
Sharpley | 2007 | Australia | 183 | 69.2 | Localised | Post-treatment |
Sharpley | 2009 | Australia | 150 | 69.8 | Localised | Post-treatment |
van Tol-Geerdink | 2006 | Holland | 118 | 70 | Localised | Pretreatment |
Van den Berg | 2009 | Holland | 129 | 64.9 | Localised | On-treatment (active surveillance) |
Van den Berg | 2010 | Holland | 129 | 64.6 | Localised | On-treatment (active surveillance) |
Monga | 2001 | USA | 40 | 67.6 | Localised | Pretreatment to Post-treatment |
Korfage | 2006 | Holland | 299 | 65.4 | Mixed | Pretreatment Post-treatment |
Bitsika | 2009 | Australia | 381 | No data | Localised | Post-treatment |
Nordin | 2001 | Sweden | 118 | No data | Localised & Advanced | Pretreatment |
Burnet | 2007 | England | 329 | 68.8 | Localised | On-treatment and post-treatment |